drug and therapy bulletinhpspc.in/pdf/drug_therapy_25_jun_2019.pdf · 2019-06-25 · pharma news...
TRANSCRIPT
DRUG AND THERAPYBULLETIN
HIMACHALPRADESHSTATEPHARMACYCOUNCIL
DRUGINFORMATIONCENTER
LAUREATE INSTITUTE OF PHARMACY, KATHOG, DISTT. KANGRA, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
Toll Free: 18001210443
Issue 21|Volume 3|Jun 2019
ContentsDrug Updates
Pharma News
Press Cutting
DRUG AND THERAPY BULLETIN
Content
EDITORIAL
AdvisoryBoard
Dr. Navneet Marwah, Mr. Sanjeev Pandit, Dr. Manoj Kumar, Dr. Ranjit Singh, Prof. CPS Verma,
Dr. Poonam Sandhu, Dr. Rajender Guleria,Mr. Arvind Kumar,Mr. Bihari Lal Gupta,Mr, Hemant Sharma,
Mr.RakeshChandel,Mr.PraveenUpadhya,Mr.KamashwarChauhan,Mr.LokeshKumar,Mr.VishalKumar,
Mr.Y.S.Chandel,Mr.BirbalSharma,Mr.ManojKumar,Mr.YogeshVerma,Mr.SurenderNadda,Dr.Parshuram
Patron
Mr.GopalKrishanSharmaandDr.RanSingh
Editor-in-Chief
Dr.KamleshNaikandDr.M.S.Ashawat
Co-Editors
Dr.VinayPanditandMr.AnkushSharma
DrugUpdates
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
VraylarforBipolarDepression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
PiqrayforPIK3CA-MutatedBreastCancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
JakafinowforGVHD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
Zolgensma:1stInfantSMAGeneTherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
MidazolamNasalSprayApproved. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Fragmin:1stPedanticoagulant . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
GattexforPediatricSBS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
VenclextaPlusGazyvaforCLL/SLL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Xeominfor1stlinetreatmentofBlepharospasm. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
EyleaforDiabeticRetinopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
FirstBiomarker-DrivenHCCTherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1
Content (Continued)
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
RuzurgiforPediatricsLEMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Vyndaqel,VyndamaxforATTR-CM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
KadcylaNowforEBC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
QternmetXRforType2Diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
TibsovoforNewlyDiagnosedAML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
FirstFDAapprovedDengueVaccine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
MavyretforPediatricUse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
KalydeconowforYoungerInfants. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
BenlystaforPediatricSLE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
HealthNews
VitaminDmayhelpcancerpatientslivelonger:research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Thyroid,irondeficiency,stresscanleadtohairfall:Doctors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Herbalmedicinesaidnewbornsdigestivesystem:Expert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
E-cigaretteuse,flavoringsmayincreaseheartdiseaserisk. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Licoriceteacauseshypertensiveemergencyinpatient . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Aspirin'safe'forbrainstrokepatients:Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Unsaltedtomatojuicecanlowerbloodpressureandcholesterollevelinadults. . . . . . . . . . . . . . . . . . 9
Antibioticusecanincreasenervedamagerisk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Scientistsdiscovernovelgenesresponsibleforregulatingmusclecells . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Researchersdiscoverplacentalstemcellsthatcanregenerateheartafterheartattack . . . . . . . . . . 11
One-offinjectionmaydrasticallyreduceheartattackrisk. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Arsenicindrinkingwaterdamagesheartsofyoungadults,studysays . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Whysleepinglessthan7hoursmayharmyourhealth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14–15PressCutting
2
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
VraylarforBipolarDepression
On May 28, 2019, the US FDA expanded the
Òindication for Vraylar (R) (cariprazine) oral
tablets to treat depressive episodes associated
withbipolarIdisorderinadultpatients.Approval
for this indication is based on 3 trials in which
cariprazine demonstrated an increase over
placebo from basel ine to week 6 on the
MontgomeryAsbergDepressionRatingScaletotal
score.Withthisapproval,theboxedwarningwas
updated to include awarning regarding suicidal
thoughtsandbehaviors.
The prescribing information can be found at:
https://www.allergan.com/assets/pdf/vraylar_pi.
Piqray for PIK3CA- Mutated Breast
Cancer
ÒOnMay24,2019, theUSFDAapprovedPiqray
(alpelisib) oral tablets indicated in combination
withfulvestranttotreatpostmenopausalwomen,
and men, with hormone receptor (HR)-positive,
human epidermal growth factor receptor 2
(HER2)-negative, PIK3CA-mutated, advanced or
metastatic breast cancer as detected by an FDA-
approvedtestfollowingprogressiononorafteran
endocrine-basedregimen.Piqray,whichisthefirst
drug to treatHR+/HER2-advancedbreastcancer
patientswithaPIK3CAmutation,incombination
with fulvestrant significantly prolonged median
progression-free survival compared with
fulvestrantaloneintheSOLAR-1clinicaltrial
Prescribing information can be found at:
https://www.accessdata.fda.gov/drugsatfda_docs/
label/2019/212526s000lbl.pdf.
JakafinowforGVHD
On May 24, 2019, the US FDA approved a new
ÒindicationforJakafi (ruxolitinibphosphate)oral
tablets for the treatment of steroid-refractory
acute graft-versus-host disease (GVHD) in adult
and pediatric patients 12 years of age or older.
Jakafi, whichwas granted breakthrough therapy
andorphandrugdesignationsforthisindication,
wasapprovedbasedonoverallresponseratedata
fromtheREACH1trial.
Prescribing information can be found at:
https://www.accessdata.fda.gov/drugsatfda_docs
/label/2019/202192s017lbl.pdf.
Zolgensma: 1st Infant SMA Gene
Therapy
On May 24, 2019, the US FDA approved
ÒZolgensma (onasemnogeneabeparvovec-xioi)IV
suspension indicated to treat pediatric patients
youngerthan2yearsofagewithspinalmuscular
atrophy (SMA) with bi-allelic mutations in the
survivalmotorneuron1(SMN1)gene.Zolgensma,
an adeno-associated virus vector-based gene
therapy that targets the cause o f SMA,
demonstrated significant improvement in ability
to reach developmental motor milestones (eg,
headcontrolandtheabilitytositwithoutsupport)
compared with the natural history of infantile-
onsetSMAinanongoingclinicaltrial.
Drug Updates
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
Prescribing information can be found at:
https://www.avexis.com/content/pdf/prescribing_
information.pdf.
MidazolamNasalSprayApproved
ÒOnMay20,2019,theUSFDAapprovedNayzilam
(midazolam) nasal spray indicated for the acute
treatmentof intermittent, stereotypicepisodesof
frequentseizureactivity(ie,seizureclusters,acute
repetitiveseizures)thataredistinctfromapatient's
usualseizurepatterninpatientswithepilepsy12
yearsofageorolder.Nayzilam,the firstandonly
nasal formulation for treating cluster seizures,
demonstrated effectiveness in a clinical trial in
whichasignificantlyhigherpercentageofpatients
treatedwithnasalmidazolamachievedtheprimary
efficacyendpoint(ie,terminationofseizureswithin
10minutesafter the initialblindeddoseof study
drugand theabsenceof a recurrenceof seizures
within6hoursoftheinitialblindeddoseofstudy
drug)comparedwiththosetreatedwithplacebo.
Prescribing information can be found at:
https://www.accessdata.fda.gov/drugsatfda_docs/
label/2019/211321s000lbl.pdf.
Fragmin:1stPedanticoagulant
OnMay16,2019,theUSFDAexpandedtheuseof
ÒFragmin (dalteparin sodium) subQ injection to
includepediatricpatients1monthofageorolder
for the treatment of symptomatic VTE. Fragmin,
thefirstanticoagulantforpediatricusetogainFDA
approval, was granted priority review for this
expandedindicationandcarriesaboxedwarning
forspinalandepiduralhematomas.
Prescribing information can be found at:
https://www.accessdata.fda.gov/drugsatfda_docs/
label/2019/020287s072lbl.pdf.
GattexforPediatricSBS
OnMay16,2019,theUSFDAexpandedtheuseof
ÒGattex (teduglutide) subQ injection to include
pediatric patients 1 year of age and older with
shortbowelsyndrome(SBS)whoaredependent
on parenteral support (PS). Gattex, which was
or ig inal ly approved in adults with SBS ,
demonstratedefficacyinapediatricclinicaltrialin
whichteduglutidereducedthevolumeofdailyPS
requiredandtimespentadministeringPS.
Prescribing information can be found at:
https://www.shirecontent.com/PI/PDFS/Gattex_U
SA_ENG.pdf.
VenclextaPlusGazyvaforCLL/SLL
On May 15, 2019, the US FDA approved a new
ÒindicationforVenclexta (venetoclax)oraltablets
incombinationwithGazyva(R)(obinutuzumab)IV
injection for previously untreated patients with
chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL). Venclexta and
Gazyva combination therapy,whichwas granted
breakthrough therapy designation for this
indication, demonstrated superior progression-
free survival compared with chlorambucil plus
obinutuzumabinaclinicaltrial.
Prescribing information can be found at:
http://www.rxabbvie.com/pdf/venclexta.pdf.
3
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
4
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
Xeominfor1stlinetreatmentof
Blepharospasm
On May 13, 2019, the US FDA approved an
Òexpanded indication for Xeomin (incobotu-
linumtoxinA) IM injection for the first-line
treatment of blepharospasm in adult patients.
Xeomin,whichwasapprovedforblepharospasmin
adult patientswhowerepreviously treatedwith
Botox(R)(onabotulinumtoxinA)IMinjection,was
approvedforthisexpandedindicationbasedona
clinical trial in which patients treated with
incobotul inumtoxinA showed signif icant
improvement comparedwith those treatedwith
placebo.
Prescribing information can be found at:
https://www.accessdata.fda.gov/drugsatfda_docs/
label/2019/125360s074lbl.pdf.
EyleaforDiabeticRetinopathy
On May 13, 2019, the US FDA expanded an
Òindication for Eylea (aflibercept) intravitreal
injection to include all stages of diabetic
retinopathy.Previouslyapprovedforpatientswith
diabeticretinopathywithmacularedemaonly,this
indication allows all patients suffering from the
diseasetohaveareductioninriskofgoingblind.
Approvalfortheexpandedindicationwasbasedon
the PANORAMA trial that demonstrated a
reduction in risk of developing proliferative
diabetic eye disease by 85% to 88% after being
treatedwith16-weekor8-weekdosingregimens,
respectively.
Prescribing information can be found at:
https://www.regeneron.com/sites/default/files/
EYLEA_FPI.pdf.
FirstBiomarker-DrivenHCCTherapy
On May 13, 2019, the US FDA approved a new
Òindication for Cyramza (ramucirumab) IV
injection as a single agent for the treatment of
patientswithhepatocellularcarcinoma(HCC)who
have an a lpha fetoprotein (AFP) of 400
nanograms/mLorgreaterandhavebeentreated
with sorafenib. Cyramza, which is already
approved for gastric, non-small cell lung, and
colorectalcancer,wasapprovedforthisindication
basedon significantly prolongedoverall survival
and progression-free survival compared with
placeboinaclinicaltrial.Additionally,theFDAhas
removed the boxed warning from the Cyramza
prescribinginformation.
Prescribing information can be found at:
http://uspl.lilly.com/cyramza/cyramza.html.
RuzurgiforPediatricsLEMS
ÒOnMay6,2019, theUSFDAapprovedRuzurgi
(amifampridine) oral tablets indicated to treat
Lambert-Eaton myasthenic syndrome (LEMS) in
pediatricpatients6yearstoyoungerthan17years
ofage.Ruzurgi,whichisthefirstFDAapprovalofa
treatment specifically for pediatric patientswith
LEMS,wasapprovedbasedonadequateandwell-
controlledstudiesofthedruginadultswithLEMS.
Prescribing information can be found at:
https://www.accessdata.fda.gov/drugsatfda_docs/
5
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
label/2019/209321s000lbl.pdf.
Vyndaqel,VyndamaxforATTR-CM
ÒOnMay3,2019,theUSFDAapprovedVyndaqel
(tafamidis meglumine) oral capsules and
Vyndamax(TM)(tafamidis)oralcapsulesindicated
for the treatment of the cardiomyopathy ofwild
type or hereditary transthyretin-mediated
amyloidosis (ATTR-CM) in adults to reduce
cardiovascular mortality and cardiovascular-
relatedhospitalization. Vyndaqel andVyndamax,
which are the first FDA-approved therapies for
ATTR-CM,havethesameactivemoiety,tafamidis,
buttheyarenotsubstitutableonamg-to-mgbasis
andtheirrecommendeddosesdiffer.
Prescribing information can be found at:
http://labeling.pfizer.com/ShowLabeling.aspx?id=
11685.
KadcylaNowforEBC
On May 3, 2019, the US FDA approved a new
Òindication for Kadcyla (ado-trastuzumab
emtansine)IVinjectionfortheadjuvanttreatment
ofpatientswithHER2-positiveearlybreastcancer
(EBC) who have residual invasive disease after
neoadjuvant taxane and trastuzumab-based
treatment.Kadcyla,whichisalreadyapprovedfor
metastatic breast cancer, was approved for this
indication based on a significantly reduced
invasivedisease-freesurvivalratecomparedwith
trastuzumabintheKatherineTrial.
Prescribing information can be found at:
https://www.accessdata.fda.gov/drugsatfda_docs/
label/2019/125427s105lbl.pdf.
QternmetXRforType2Diabetes
ÒOnMay3,2019,theUSFDAapprovedQternmet
XR (dapagliflozin/metformin hydrochloride/
saxagliptin)oraltabletsasanadjuncttreatmentto
diet and exercise to improve glycemic control in
adultswithtype2diabetes.ApprovalforQternmet
XRcomesafter2trialsdemonstratedanincreasein
t h e numbe r o f p a t i e n t s a c h i ev i n g t h e
recommendedHbA1ctreatmentgoal.QternmetXR
carriesablackboxwarningforlacticacidosis.
Prescribing information can be found at:
https://www.accessdata.fda.gov/drugsatfda_docs/
label/2019/210874s000lbl.pdf.
TibsovoforNewlyDiagnosedAML
On May 2, 2019, the US FDA approved a new
Òindication forTibsovo (ivosidenib) oral tablets
for the treatment of newly-diagnosed acute
myeloid leukemia (AML) with a susceptible
isocitrate dehydrogenase-1 (IDH1) mutation as
detectedbyanFDA-approvedtestinadultpatients
who are 75 years of age or older or who have
comorbidities that preclude use of intensive
induction.Tibsovo,which isalreadyapproved to
treat adult patients with relapsed or refractory
AMLandanIDH1mutation,wasgrantedpriority
review and accepted under the FDA's Real-Time
OncologyReviewpilotprogrammakingitthefirst
and only therapy to gain FDA approval for this
indication.
Prescribing information can be found at:
6
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
https://www.accessdata.fda.gov/drugsatfda_docs/
label/2019/211192s001lbl.pdf.
FirstFDAapprovedDengueVaccine
ÒOnMay1,2019,theUSFDAapprovedDengvaxia
(denguetetravalentvaccine,live)subQinjectionto
prevent dengue disease caused by dengue virus
serotypes 1, 2, 3, and 4 in pediatric patients 9
through16yearsofagewithlaboratory-confirmed
previous dengue infection and living in endemic
areas.Dengvaxia, the firstFDA-approveddengue
disease vaccine, demonstrated efficacy in
preventingdenguediseaseinclinicaltrials.
Prescribing information can be found at: https://
vaccineshoppe.com/assets/pdf/DengvaxiaPI.pdf.
MavyretforPediatricUse
OnApril30,2019,theUSFDAexpandedtheuseof
ÒMavyret (glecaprevir/pibrentasvir)oral tablets
to include pediatric patients 12 years of age or
olderwithchronichepatitisCvirusgenotype(GT)
1,2,3,4,5or6infectionwithoutcirrhosisorwith
compensatedcirrhosis.Mavyret,whichisalready
approvedinadultpatients,demonstratedefficacy
in clinical trialswhere 100%of patients treated
with glecaprevir/pibrentasvir had no virus
detected in theblood12weeksaftercompleting
therapy.
Prescribing information can be found at:
https://www.rxabbvie.com/pdf/mavyret_pi.pdf.
KalydeconowforYoungerInfants
OnApril30,2019,theUSFDAexpandedtheuseof
ÒKalydeco (ivacaftor) oral granules to include
pediatricpatients6monthsof ageorolderwith
cystic fibrosis (CF) who have 1 mutation in the
conductance regulator (CFTR) gene that is
responsivetoivacaftorbasedonclinicaland/orin
vitro assay data. Kalydeco, which was already
approvedintheUStotreatpediatricpatients12
monthsofageorolder,isthefirstCFTRmodulator
togainapproval ineligible infantsasyoungas6
monthsofage.
Prescribing information can be found at:
https://www.accessdata.fda.gov/drugsatfda_docs/
label/2019/203188s029,207925s008lbl.pdf.
BenlystaforPediatricSLE
OnApril26,2019,theUSFDAexpandedtheuseof
ÒBenlysta (belimumab) IV injection to include
pediatric patients 5 years or olderwith systemic
lupuserythematosus(SLE).Benlysta,thefirstdrug
to gain FDA approval for pediatric patients with
SLE, demonstrated efficacy in a clinical trial in
whichasignificantlygreaterproportionofpediatric
patients treated with intravenous belimumab
achievedthecompositeprimaryendpointofanSLE
response index (SRI-4) compared with those
treatedwithplaceboplusstandardtherapy.
Prescribing information can be found at:
www.gsksource.com/pharma/content/dam/Glaxo
SmithKline/US/en/Prescribing_Information/Benly
sta/pdf/BENLYSTA-PI-MG-IFU.PDF.
Ref:www.micromedexsolutions.com
7
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
VitaminDmayhelpcancerpatientslive
longer:research
VitaminDsupplements,iftakenforatleastthree
years, could add years to the lives of cancer
patients,astudyhasfound.Theresearchersfrom
MichiganStateUniversityintheUSsuggestthatthe
vitamincarriessignificantbenefitsotherthanjust
contributingtohealthybones.
"VitaminDhadasignificanteffectonloweringthe
risk of death among those with cancer, but
unfortunatelyitdidn'tshowanyproofthatitcould
protect against getting cancer," saidTarekHaykal,
from Michigan State University. The researchers
lookedatdata related todiseaseprevention from
morethan79,000patientsinmultiplestudiesthat
randomly compared the use of vitamin D to a
placebooveratleastathree-yearperiod.
Ref:www.health.economictimes.indiatimes.com
Thyroid,irondeficiency,stresscanlead
tohairfall:Doctors
Hair loss or alopecia is still considered a beauty-
relatedproblemandpeopleprefertousecosmetic
solutions and alternative treatments provided by
corporate clinics. However, alopecia needs to be
treated medically by dermatologists as reasons
behind it could defer— from iron deficiency to
psychologicalstress.DrPradeepSethifromAIIMS,
NewDelhi,saidpeopleshouldvisitadermatologist
instead of going to corporate hair fall clinics and
searchingforonlinehairtransplantoptions.“These
clinics and websites call themselves as trained
practitionersoftrichology.Thisisjustabranchof
dermatology concerned with hair and scalp.
Dermatologistsbestunderstandthereasonsbehind
hairlossandtreatthemaccordingly,”hesaid.
Endocrinologist Parimal Tayade said diabetes,
thyroiddiseaseandandrogenexcesscouldbethe
reasons behind hair fall. “Sudden and excessive
hairlosscouldbeearlysignsofdiabetesorthyroid.
It's always good to check blood sugar before
startingtreatmenttostophairfall,”DrTayadesaid.
Psychiatrist Vikas Bhute said life has become
stressfulwhichisoneoftheleadingreasonsbehind
hairfall.
DietitianMeghnaKumre shared some important
diet-relatedtipstoavoidhairfall.“Irondeficiency
couldbethereasonbehindhairfall.Peopleprefer
toeatspinachwhenitcomestoirondeficiency.But,
wall nuts, cashews, rajma and black-eyed pea
(chawli beans) are richer sources of iron than
spinach,”shesaid.
Hairfallcontrol
¨Irondeficiencycouldbethemajorreason.
¨Improveironabsorptioncapacityofbodytodeal
withit.
Pharma News
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
8
whileseveralof liquidsweremoderatelytoxicto
the endothelial cells, the cinnamon andmenthol
flavored e-liquids significantly decreased the
viabilityofthecellsincultureevenintheabsence
ofnicotine.
Exposure to the e-liquids also increased the
relative levels of reactive oxygen species-
molecules that can cause DNA damage- and the
level of molecules associated with programmed
celldeath.
Ref:wwwmed.stanford.edu
Licoriceteacauseshypertensive
emergencyinpatient
Licorice tea, apopularherbal tea, isnotwithout
healthrisks,asacasestudyofamanadmittedto
hospital for a high-blood pressure emergency
demonstrates in CMAJ (Canadian Medical
Associationjournal)
Productscontaininglicoricerootextractcanraise
blood pressure causes water retention and
decreasepotassiumlevelsifconsumedinexcess.
Ref:medicalxpress.com
Aspirin‘safe’forbrainstrokepatients:
Study
Peoplewhohavesufferedbrainhaemorrhagecan
take commonmedicines such as aspirinwithout
raising their risk of another stroke, suggest
researchers.AspirinandClopidogrel,alsoknown
antiplatelet medicines are often prescribed to
olderpeoplebecausetheycanlowerriskofheart
attackandstrokecausedbyabloodclot.
Although doctors wary of recommending
antiplateletmedicinesforstrokepatients,fearing
theriskofanotherbrainbleeding,thisnewstudy
called"Restart",publishedinTheLancetjournal,
has found thatbrainhaemorrhage survivors can
"safely"continuetotakeantiplateletmedicinesto
reducetheirriskoffutureheartattacksorstrokes.
Ref:www.health.economictimes.indiatimes.com
Unsaltedtomatojuicecanlowerblood
pressureandcholesterollevelinadults
Unsalted tomato juiceworkswonders for adults
who are at risk of cardiovascular disease.
Researchers have found that drinking unsalted
tomato juice can lower blood pressure and
9
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
¨Gardengreenswith lemonjuice increases iron
absorption.
¨Amixture of poppy and sesame seeds can be
usedindailydiet.
¨Early thyroid could be the reason behind the
problem.
¨Thisdoesn'tneedmeditationassimpledietary
changeswilldo.
¨Intake of carbohydrates and proteins in daily
dietshouldbemaintained.
¨Usingdietarysupplementsorfollowingin-trend
dietpatternsshouldbeavoided.
¨Diarrhoeaandaciditycouldalsobethereasons.
¨Over-consumption of tea, coffee should be
avoided.
Ref:www.health.economictimes.indiatimes.com
Herbalmedicinesaidnewborns
digestivesystem:Expert
Medicines with natural ingredients like Dill Oil,
Guduchi and Amalaki help regularise bowel
movementsandcontroldigestivedisturbancesin
babies,anexperthassaid.
"Theinitialthreeyearsoflifearethemostcrucial
for a baby's growth and development, and the
digestivesystemplaysanimportantrole.Healthy
digestionsupportshealthygrowthinbabiesandis
vital for their overall well-being," said Rajesh
Kumawat, Head, Medical Services and Clinical
Development, theHimalaya Drug Company. To
relievethebaby'sdigestivediscomfort,theparents
mustensurethatthebabyisfedinsmallquantities
atfrequentintervalsandincludeenoughliquids,he
said.Thiswillhelptodigestthefood.
Ref:health.economictimes.indiatimes.com
E-cigaretteuse,flavoringsmay
increaseheartdiseaserisk
Researchers found that when grown in a
laboratory, endothelial cells exposed to the e-
liquidsortobloodcollectedfrome-cigaretteusers
shortly after vaping are less viable and exhibit
significantly increased levels of molecules
implicatedinDNAdamageandcelldeath.Thecells
arealsolessabletoformnewvasculartubesandto
migrate and participate in wound healing. The
severityofthedamage,aspectsofwhichoccureven
in theabsenceofnicotine,variesamongpopular
flavors, the researchers said. Cinnamon and
mentholwerefoundtobeparticularlyharmful.
The researchers investigated the effect of six
different popular e-liquid flavors- fruit tobacco,
sweet tobacco, with caramel and vanilla, sweet
butter scotch, cinnamon and menthol- with
nicotinelevelsof0,6and18mg/mlonendothelial
cellsderivedfromhumaniPScells.Theyfoundthat
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
10
cholesterol level in adults who are at risk of
cardiovasculardisease,accordingtoastudy.
For the study, published in the journal of Food
ScienceandNutrition,researchersfromtheTokyo
MedicalandDentalUniversityinJapanexamined
nearly500residents-184malesand297females.
Itwasfoundthatbloodpressurein94participants
withuntreatedpre-hypertensionorhypertension
dropped significantly. Tomato juicemayhelp in
boostinghearthealthbycuttingdowntheriskof
heart-related ailments. High LDL (or bad)
cholesterol levels in 125 participants decreased
fromanaverageof155to149.9mg/dL,saidthe
study. According to researchers, these beneficial
effectsweresimilaramongmenandwomenand
alsofordifferentagegroups.
Ref:www.economictimes.indiatimes.com
Antibioticusecanincreasenerve
damagerisk
ResearchfromtheUniversityofDundeehasshown
that a commonly used class of antibiotics may
increaseapatient'sriskofsufferingaseriousand
potentially permanent form of nerve damage by
almost50percent.Peripheralneuropathyhaslong
been recognised as a potential side effect of
fluoroquinolone antibioticsbut itwasnot known
howstrongthisassociationwasandhowitcould
beaffectedbythelengthoftreatment,orbyageand
gender.Researchers ledbyDr.DanielMorales,of
the University's School of Medicine, looked at a
databaseof1.3millionadultsissuedoneormore
prescriptions of fluoroquinolone or amoxicillin-
clavulanate antibiotics with no diagnosis of
peripheralneuropathyattheoutsetoftreatment.
They found that current use of systemic fluoro-
quinoloneantibioticsappearedtoincreasetherisk
ofperipheralneuropathyby47percent,causingan
additional2.4casesper10,000patientsperyearof
treatment.Apersonprescribedwithamoxicillin-
clavulanate was not significantly more likely to
experienceperipheralneuropathy.
Theriskwashigherformenandrosewithageand
with the length of fluoroquinolone treatment. A
peripheral neuropathy diagnosis remained more
likelytobediagnosedforuptosixmonthsafterthe
fluoroquinolone prescription. "The safety of
fluoroquinolone antibiotics has received a lot of
attention regarding theirpotential to cause long-
termsideeffectsinsomepeople,"hesaid."Oneof
theseisperipheralneuropathywherenerves,most
commonly affecting the lower limbs, can be
affected, leading to numbness, pain, or problems
with balance. "Fluoroquinolones are effective
antibiotics but health care professionals should
recognise that peripheral neuropathymay rarely
occurfollowingfluoroquinolonetherapy.Antibiotic
stewardshipiscriticallyimportanttoensurethese
valuablemedicinesareusedappropriately.
Ref:www.medicalxpress.com
Scientistsdiscovernovelgenes
responsibleforregulatingmusclecells
YorkUniversityscientistshaveuncoveredaunique
setofgenesthatplayaroleinmusclecellulargene
11
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
expressionanddifferentiationwhichcouldleadto
newtherapeutic targets toprevent thespreadof
musclecancer.
Theresearchersanalyzedgenenetworksinmuscle
cells and found that the Smad7 and β-catenin
proteins work cooperatively inside the body to
regulate muscle cell differentiation, growth and
repair. When these regulatory proteins work in
harmony,theycontrolthepathwayfornormalgene
expression, resulting in normal skeletal muscle
cells.
Ref:www.medicalxpress.com
Researchersdiscoverplacentalstem
cellsthatcanregenerateheartafter
heartattack
Researchers at the Icahn School of Medicine at
Mount Sinai have demonstrated that stem cells
derivedfromtheplacentaknownasCdx2cellscan
regeneratehealthyheartcellsafterheartattacksin
animalmodels.Thefindings,publishedintheMay
20issueofProceedingsoftheNationalAcademyof
Sciences(PNAS),mayrepresentanoveltreatment
forregeneratingtheheartandotherorgans.
"Cdx2cellshavehistoricallybeenthoughttoonly
generate the placenta in early embryonic
development,butneverbeforewereshowntohave
theabilitytoregenerateotherorgans,whichiswhy
thisissoexciting.
These findings may also pave the way to
regenerative therapy of other organs besides the
heart," saidprincipal investigatorHinaChaudhry,
MD, Director of Cardiovascular Regenerative
MedicineattheIcahnSchoolofMedicineatMount
Sinai. "They almost seem like a super-charged
populationofstemcells,inthattheycantargetthe
site of an injury and travel directly to the injury
throughthecirculatorysystemandareabletoavoid
rejectionbythehostimmunesystem."Thisteamof
MountSinairesearchershadpreviouslydiscovered
thatamixedpopulationofmouseplacental stem
cellscanhelptheheartsofpregnant femalemice
recoverafteraninjurythatcouldotherwiseleadto
heart failure. In that study, they showed that the
placentalstemcellsmigratedtothemother'sheart
anddirectlytothesiteoftheheartinjury.Thestem
cellsthenprogrammedthemselvesasbeatingheart
cellstohelptherepairprocess.
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
The new study was aimed at determining what
typeofstemcellsmadetheheartcellsregenerate.
TheinvestigatorsstartedbylookingatCdx2cells,
themostprevalentstemcelltypeinthepreviously
identified mixed population, and found them to
comprise thehighestpercentage (40percent)of
thoseassistingtheheartfromtheplacenta.
Researchers noted two other properties of the
Cdx2cells:theyhavealltheproteinsofembryonic
stemcells,whichareknowntogenerateallorgans
of the body, but also additional proteins, giving
themtheabilitytotraveldirectlytotheinjurysite,
which is somethingembryonicstemcells cannot
do, and they appear to avoid the host immune
response.Theimmunesystemdidnotrejectthese
cells when administered from the placenta to
anotheranimal.
Ref:www.medicalxpress.com
One-offinjectionmaydrastically
reduceheartattackrisk
Doctors in the US have announced plans for a
radicalgenetherapythataimstodrasticallyreduce
theriskofheartattack,theworld'sleadingcauseof
death, with a one-off injection. The researchers
hopetotrialthetherapywithinthenextthreeyears
inpeoplewithararegeneticdisorderthatmakes
thempronetoheartattacksintheir30sand40s.If
the treatment proves safe and effective in the
patients,doctorswillseekapprovaltoofferthejab
toawiderpopulation.
“Thetherapywillberelevant,wethink,toanyadult
atriskofaheartattack,”saidSekarKathiresan,a
cardiologist and geneticist at Harvard Medical
Schoolwhowillleadtheeffort.“Wewantthisnot
onlyforpeoplewhohaveheartattacksatayoung
agebecauseofageneticdisorder,but forgarden
varietyheartattacksaswell.”
HeartdiseaseistheNo1killerinmanycountries.
Theestimated18milliondeathsareattributedto
theconditioneveryyear,thevastmajorityofwhich,
about 85%, are caused by heart attacks and
strokes.
Peoplewhoareatriskofaheartattackaretypically
putonarangeofmedicines,suchasbloodthinners,
cholesterol-lowering statins, and pills for high
bloodpressure.Mostmustbetakendaily forthe
rest of the person's life, butmany drift off their
medicationovertime.
Ref:www.theguardian.com
Arsenicindrinkingwaterdamages
heartsofyoungadults,studysays
"Thehigherthearseniccontentindrinkingwater,
thegreaterthedamagetotheheart,"saidPichler,
who is amedical specialist atHospitalHietzing/
12
13
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
HeartCenterClinicFloridsdorfinVienna,Austria.
Long-termexposuretoinorganicarsenic,ahuman
poison thatoccursnaturally in theEarth's crust,
hasbeenlinkedtovariouscancers,kidneydamage,
hypertension,cardiovasculardiseaseanddiabetes.
Organicarsenic,suchaswhat'sfoundinseafood,is
notknowntobetoxictohumans.Thougharsenic
canbefoundintheairandsoil,theWorldHealth
Organization says the greatest threat to public
healthgloballycomesfromgroundwater,whichis
contaminated as it flows through rocks and
mineralscontainingarsenic.
Ref:www.edition.cnn.com
Whysleepinglessthan7hoursmay
harmyourhealth
The research , pub l i shed in the journa l
Experimental Physiology, shows that sleep
deprivation can increase the level of three
physiologicalregulators(microRNAs)intheblood,
which influence gene expression and play a key
roleinmaintainingvascularhealth.MicroRNAsare
smallmoleculesthatsuppressgeneexpressionof
certain proteins in cells. The exact function of
circulating microRNAs in the cardiovascular
systemandtheirimpactoncardiovascularhealthis
receivingalotofscientificattention,anddrugsare
currentlyindevelopmentforavarietyofdiseases,
including cancer, to correct impaired microRNA
signatures. For the study, which is the first to
explore the impact of insufficient sleep on
circulatingmicroRNAsignatures,researcherstook
bloodsamplesfrom24healthymenandwomen,
age 44 to 62, who had filled out questionnaires
abouttheirsleephabits.
Halfsleptsevento8.5hoursnightlywhiletheother
halfslept5 to6.8hoursnightly.They foundthat
peoplewithinsufficientsleephad40to60percent
lowercirculatinglevelsofmiR-125A,miR-126,and
miR-146athanthosewhosleptenough.
“However,itisplausiblethatpeopleneedatleast
sevenhoursofsleeppernighttomaintainlevelsof
important physiological regulators, such as
microRNAs,”hesaid.
Ref:www.business-standard.com
MOUsignedbetweenMinistryof
AYUSHandCouncilofScientificand
IndustrialResearch
A Memorandum of Understanding (MOU) was
signed between the Ministry of AYUSH and
Council of Scientific and Industrial Research
(CSIR),NewDelhi.TheMoUwassignedbyVaidya
RajeshKotecha,Secretary,MinistryofAYUSHand
Dr.ShekharC.Mande,DirectorGeneral,CSIRand
Secretary,DSIRinthepresenceofseniorofficials
from both the organizations. Speaking on the
occasion,Secretarystatedinduecognitionofthe
growing interest of traditional medicines
worldwide, there isaneedofmultiprongedand
innovativeapproachesfortheacceptanceofthis
science. He said that the combination of
traditionalhealthcareandmodernbasicscience
hasahugepossibilitytodoinnovativeandpath-
breaking researches which can be used for the
explanation of various basic concepts. DG, CSIR
apprec i a ted the ongo ing p ro j e c t s and
programmesbetweenthe twoorganizations.He
stated that enhancing the collaboration through
joint R&D efforts ranging from fundamental
science to validation and thereafter product
development,willsignificantlyhelpinthegrowth
of the Indian contributions to this important
sector,notonlynationallybut internationallyas
well.
Ref:www.pharmatutor.org
14
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
Press Cutting
Ref:DainikJagran(RashtriyaSanskaran);27-05-2019
15
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Distt Kangra, HP - 177101
Toll Free : 18001210443 |Phone: 9218428042/9459220253|E-mail: [email protected]/[email protected]
Ref:AmarUjala;08-05-2019
Ref:AmarUjala;08-05-2019
TollFree18001210443
ScanthisQuickResponse(QR)
codetoknowmore
YoumaydownloadanyQRcodescannerfrom
PlayStore/iTunes
HIMACHALPRADESHSTATE PHARMACYCOUNCIL
DRUGINFORMATIONCENTER
LaureateInstituteofPharmacy,Kathog,Distt.Kangra,HP-177101
TollFree:18001210443|Phone:09218428042/9459220253
E-mail:[email protected]/[email protected]
TollFree:18001210443|Phone:9218428042/9459220253
Foranyclarifications,anyonecandirectlycalltotheDICofficeorsendtheirquerybypost
orE-mailtothebelowaddress.
Note:Ifanyonewanttopublishhis/herarticleinthemonthlybulletinofDrug InformationCenterregardingPharmaupdates, theycansend theirarticleswith their full address and professional status on the following
threferencebefore25 ofeverymonth.
© 2
019 P
harm
a P
uls
e | in
fo@
pharm
apuls
e.in
| 9
482797901